These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 26449347)
1. Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck : First clinical experience with vismodegib for locally advanced disease. Schulze B; Meissner M; Ghanaati S; Burck I; Rödel C; Balermpas P Strahlenther Onkol; 2016 Jan; 192(1):25-31. PubMed ID: 26449347 [TBL] [Abstract][Full Text] [Related]
2. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib. Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876 [TBL] [Abstract][Full Text] [Related]
4. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279 [TBL] [Abstract][Full Text] [Related]
5. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial. Dessinioti C; Plaka M; Stratigos AJ Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979 [TBL] [Abstract][Full Text] [Related]
6. [Locally advanced basal-cell carcinoma: Combined alternative treatments beyond surgery]. Amici JM; Beylot-Barry M Ann Chir Plast Esthet; 2015 Aug; 60(4):321-5. PubMed ID: 25708732 [TBL] [Abstract][Full Text] [Related]
7. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123 [TBL] [Abstract][Full Text] [Related]
8. Identifying patients at risk for recurrent or advanced BCC. Hamid O; Goldenberg G J Drugs Dermatol; 2013 Nov; 12(11):1246-52; quiz 1253-4. PubMed ID: 24196332 [TBL] [Abstract][Full Text] [Related]
10. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma. Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490 [TBL] [Abstract][Full Text] [Related]
14. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. Zhu GA; Sundram U; Chang AL JAMA Dermatol; 2014 Sep; 150(9):970-3. PubMed ID: 24740281 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma. Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798 [TBL] [Abstract][Full Text] [Related]
16. A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib. Lucero OM; Fitzmaurice S; Thompson C; Leitenberge J Dermatol Online J; 2018 Feb; 24(2):. PubMed ID: 29630158 [TBL] [Abstract][Full Text] [Related]
17. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. Cirrone F; Harris CS Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338 [TBL] [Abstract][Full Text] [Related]
18. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp. Tauber G; Pavlovsky L; Fenig E; Hodak E J Am Acad Dermatol; 2015 Nov; 73(5):799-801. PubMed ID: 26320385 [TBL] [Abstract][Full Text] [Related]
19. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma. Proctor AE; Thompson LA; O'Bryant CL Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609 [TBL] [Abstract][Full Text] [Related]
20. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]